Using modified stem cell particles to treat degenerative disc disease
Official title: Extracellular vesicles produced by CRISPR-activated MSCs: A potential therapy for degenerative disc disease
Funded at Rochester Institute of Technology · NIH-10873279 · Data updated 2026-11-12
This study is exploring a new treatment for low back pain caused by degenerative disc disease, using tiny particles from specially modified stem cells to help reduce inflammation and promote healing in your discs, which could lead to less pain and better movement.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rochester Institute of Technology NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $163,110 |
| NIH project number | 5R21AR081987-02 |
| Project ID | NIH-10873279 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing chronic low back pain due to degenerative disc disease.
✕Less likely to help
Patients with acute back pain not related to degenerative disc disease may not benefit from this research.
What this research studies
This research investigates the use of extracellular vesicles (EVs) produced by genetically modified mesenchymal stem cells (MSCs) as a potential therapy for degenerative disc disease (DDD), a common cause of low back pain. The approach focuses on enhancing the regenerative properties of these EVs to combat inflammation and promote healing in the intervertebral discs. By modifying MSCs to increase the production of specific proteins, the study aims to improve the therapeutic effects of the EVs without the complications associated with direct cell therapies. Patients may benefit from a novel treatment option that could alleviate pain and improve mobility.
Why it matters
Potential benefit: If successful, this research could provide a new, less invasive treatment option for patients suffering from degenerative disc disease.
How similar studies have gone: While the use of extracellular vesicles in therapy is a relatively novel approach, preliminary studies have shown promise in similar applications.
Where this research is happening
-
Rochester Institute of Technology
Rochester, United States Active
Researchers
- Principal investigator: Wuertz-Kozak, Karin — Rochester Institute of Technology
- Study coordinator: Wuertz-Kozak, Karin
Related research
Other NIH-funded projects on the same topics.
-
Bone marrow concentrate injection added to lumbar microdiscectomy
This trial tests whether adding a bone marrow aspirate concentrate injection during lumbar microdiscectomy helps adults recover better than surgery alone.
-
IDCT (Intradiscal Cell Therapy) for single-level mild-to-moderate lumbar degenerative disc disease
This will test whether injecting IDCT (rebonuputemcel) into one degenerating lower-back disc can reduce chronic low back pain in adults with mild-to-moderate lumbar degenerative disc disease.
-
Novosis Putty used with transforaminal lumbar interbody fusion for lumbar degenerative disc disease
The trial will test whether using Novosis Putty during transforaminal lumbar interbody fusion helps adults with lumbar degenerative disc disease heal better compared with standard care.
-
Evaluating a new treatment for painful disc degeneration
This study is testing a new non-surgical treatment for people with painful disc degeneration to see if it can help relieve their back pain when other treatments haven't worked.
-
Evaluating a hybrid surgical approach for cervical degenerative disc disease
This study is testing a new combined surgery for people with neck pain from two damaged discs to see if it works better and is safer than traditional surgery.
-
Evaluating LDGraft for lumbar spine surgery
This study is testing a new device called LDGraft to see if it is safe and effective for patients having surgery for lower back problems compared to using human tissue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.